Global Contraceptive Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Contraceptive Devices Market Size

• The global contraceptive devices market size was valued atUSD 10.89 billion in 2024and is expected to reachUSD 18.03 billion by 2032, at aCAGR of 6.50%during the forecast period
• This growth is driven by factors such as increasing awareness of family planning, rising demand for non-invasive contraceptive methods, and advancements in product offerings

Contraceptive Devices Market Analysis

• Contraceptive devices are critical tools used in various eye surgeries, providing magnified, high-resolution views of the eye’s internal structures. They are essential for procedures such as cataract surgery, retinal surgery, andcorneal transplants
• The demand for these microscopes is significantly driven by the increasing prevalence of age-related eye conditions and advancements in surgical techniques
• North America is expected to dominate the contraceptive devices market with largest market share of 30.8%, due to advanced healthcare infrastructure, widespread awareness of contraceptive methods, and supportive government policies
• Asia-pacific is expected to be the fastest growing region in the contraceptive devices market during the forecast period due to improving healthcare access and the introduction of affordable contraceptive options
• The male contraceptive devices segment is expected to dominate the contraceptive devices market with the largest market share of 68.7% in 2025 due to increasing awareness and acceptance of male contraceptive options, growing demand for shared responsibility in family planning, and innovations in non-invasive methods such as gels and pills. Advances in reversible vasectomy procedures and the development of effective male contraceptive solutions are further driving this growth

Report Scope and Contraceptive Devices Market Segmentation

Contraceptive Devices Market Trends

“Rising Preference for Long-Lasting Contraceptive Solutions”

• The contraceptive devices market is witnessing a significant shift towards long-acting reversible contraceptives, such as intrauterine devices and implants, due to their extended protection and reduced need for frequent intervention ​
• This trend is driven by user preferences for convenience and reliability, leading to increased adoption of these methods over short-term options ​
• Technological advancements have led to the development of smaller, more flexible implants that are easier to insert and remove, enhancing user comfort and satisfaction ​
  • For instance, the introduction of the EnilloRing, a contraceptive vaginal ring designed for long-term use, reflects the market's response to the demand for user-friendly and effective contraceptive solutions ​
• In conclusion, the integration of digital health technologies, such as mobile apps and wearable devices, is further enhancing the appeal of long-acting contraceptives by providing users with tools to monitor usage and receive personalized recommendations ​

Contraceptive Devices Market Dynamics

Driver

“Increasing Awareness of Family Planning”

• Rising awareness of family planning globally has been a significant driver of the contraceptive devices market with educational campaigns and media outreach playing key roles in spreading information
• Governments, NGOs, and healthcare providers have collaborated on programs to promote reproductive health rights, leading to greater acceptance of contraception methods
• Access to accurate information about various contraception methods has empowered individuals, especially women, to make informed decisions about their reproductive health
• In countries like India and Africa, campaigns highlighting the benefits of contraception have led to increased usage, improving family planning outcomes and reducing unintended pregnancies
• Education about contraception has helped overcome cultural taboos, making people more open to discussing and using these devices, thus supporting market growth
• This awareness, coupled with government initiatives, continues to drive the contraceptive devices market forward

Opportunity

“Growing Demand for Contraceptive Devices”

• The growing demand for contraceptive devices in developing and emerging economies presents a significant opportunity for market expansion due to increasing urbanization, better healthcare infrastructure, and rising disposable income
• Regions like Asia-Pacific, Latin America, and parts of Africa represent untapped markets with large populations where contraceptive usage is still relatively low compared to developed countries
• The expanding middle class in countries like India, China, Brazil, and Mexico is fueling the demand for modern family planning methods, driving the market towards wider adoption
• Governments and healthcare organizations in these regions are launching awareness campaigns and introducing affordable contraceptive solutions to meet the growing demand for family planning methods
• The increased focus on women's health and empowerment, coupled with a reduction in cultural barriers, is making it easier for women to make reproductive health decisions, creating a fertile environment for market growth

Restraint/Challenge

“Regulatory and Approval Complexities”

• A major restraint in the contraceptive devices market is the complex regulatory approval process, which can delay the introduction of new products due to stringent guidelines from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
• These regulations ensure safety and efficacy but can slow the process of bringing innovative products to market, requiring extensive clinical trials, safety assessments, and comprehensive documentation
• For smaller companies and startups, meeting these rigorous regulatory requirements is especially challenging due to financial constraints, limiting their ability to innovate or quickly introduce new contraceptive solutions
• Post-market surveillance and continuous monitoring required by regulatory bodies add further complexity, as companies must ensure ongoing compliance even after product launch, which increases operational costs
• Delays in product availability due to regulatory hurdles can lead to missed market opportunities, particularly in regions with rapidly growing demand for contraceptive devices

Contraceptive Devices Market Scope

The market is segmented on the basis of product type, technology, and distribution channel.

In 2025, the male contraceptive devices segment is projected to dominate the market with a largest share in product type segment

The male contraceptive devices segment is expected to dominate the contraceptive devices market with the largest of 68.7% in 2025 due to increasing awareness and acceptance of male contraceptive options, growing demand for shared responsibility in family planning, and innovations in non-invasive methods such as gels and pills. Advances in reversible vasectomy procedures and the development of effective male contraceptive solutions are further driving this growth. As more research and development efforts focus on male contraception, the segment is expected to expand rapidly, offering men more control over reproductive health. Additionally, the changing social norms and growing gender equality in family planning are encouraging more men to consider these options.

The Hormonal Contraceptives segment is expected to account for the largest share during the forecast period in technology segment

In 2025, the hormonal contraceptives segment is expected to dominate the market with the largest market share of 73.1% due to their widespread use, proven effectiveness, and convenience. Hormonal contraceptives, including birth control pills, patches, and injections, are well-established methods that offer long-term reliability and ease of use, which continue to drive their popularity among women. Additionally, ongoing advancements in hormonal formulations that minimize side effects and improve efficacy are expected to further bolster the segment's growth. The growing awareness and accessibility of hormonal contraceptives, supported by government health programs and medical professionals, also contribute to their dominant position in the market.

Contraceptive Devices Market Regional Analysis

“North America Holds the Largest Share in the Contraceptive Devices Market”

• North America holds the largest market share of 30.8% in the contraceptive devices market
• The region's dominance is attributed to factors such as advanced healthcare infrastructure, widespread awareness of contraceptive methods, and supportive government policies
• The U.S., in particular, contributes significantly to the market with market share of 25.8%,due to high adoption rates of various contraceptive devices
• North America's established healthcare infrastructure and presence of key players like Bayer and Pfizer support market dominance
• The presence of key market players and ongoing research and development activities further bolster the region's leading position​

“Asia-Pacific is Projected to Register the Highest CAGR in the Contraceptive Devices Market”

• Asia-Pacific is projected to experience the highest growth rate in the contraceptive devices market during the forecast period
• The growth is further supported by improving healthcare access and the introduction of affordable contraceptive options
• The rapid growth is driven by increasing awareness of family planning, rising population, and government initiatives promoting contraceptive use
• Countries like China and India are major contributors to this growth due to their large populations and efforts to improve access to contraceptive methods
• The expansion of healthcare infrastructure and increasing availability of contraceptive devices in rural areas also support market growth in the region​

Contraceptive Devices Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Bayer AG (Germany)
• Pfizer Inc. (U.S.)
• Janssen Global Services, LLC (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Merck Sharp & Dohme Corp. (U.S.)
• Mylan N.V. (U.S.)
• Reckitt Benckiser Group plc. (U.K.)
• Veru Inc. (U.S.)
• Medisafe Distribution Inc. (Canada)
• CooperSurgical, Inc. (U.S.)
• Devex (U.S.)
• Mayer Laboratories, Inc. (U.S.)
• Allergan plc (Ireland)
• Agile Therapeutics (U.S.)
• HLL Lifecare (India)
• ANSELL LTD (Australia)
• Mankind Pharma (India)
• TTK HealthCare (India)
• Boehringer Ingelheim International GmbH (Austria)
• V-Care Pharma Pvt. Ltd. (India)
• VARDHAMAN LIFECARE PVT LTD (India)
• Cipla Inc. (U.S.)

Latest Developments in Global Contraceptive Devices Market

• In April 2025, trials showed that a non-hormonal male contraceptive implant, named Adam, can last for at least two years. The implant, which is inserted into the sperm ducts, blocks sperm from mixing with semen. It offers a reversible alternative to methods like condoms or vasectomies. Early results indicate its effectiveness for 24 months without adverse effects, though additional data on reversibility is still awaited. Further trials are planned to confirm long-term outcomes
• In March 2025, Daré Bioscience introduced Ovaprene, a non-hormonal, monthly contraceptive combining a barrier ring with a drug-releasing component. The device, inserted vaginally, releases an iron-based compound that impairs sperm motility, while its polymer mesh physically blocks sperm entry. Currently undergoing Phase 3 trials, Ovaprene aims to offer a non-hormonal alternative to traditional methods like hormonal IUDs and daily pills
• ​In September 2024, CooperSurgical introduced a new single-hand inserter for its Paragard intrauterine copper contraceptive (IUD), recently approved by the U.S. Food and Drug Administration (FDA). This innovative inserter is designed to simplify the insertion process, enhancing accessibility for healthcare providers and patients alike. Paragard has been a trusted option for over 30 years, offering more than 99% efficacy in preventing pregnancy for up to 10 years
• ​In June 2024, Contraline partnered with DNA Diagnostics Center (DDC) to enhance its ADAM male contraceptive trial. DDC provided an at-home sperm analysis test, enabling participants to monitor the implant's effectiveness privately. This collaboration aimed to improve participant compliance and provide real-time feedback on sperm presence, complementing the hydrogel implant's role in blocking sperm flow through the vas deferens

SKU-1061